Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.8270-0.0340 (-3.95%)
At close: 04:00PM EST
0.8301 +0.00 (+0.37%)
After hours: 07:36PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8610
Open0.8600
Bid0.8301 x 800
Ask0.9699 x 1200
Day's Range0.8240 - 0.8851
52 Week Range0.8240 - 3.1500
Volume336,715
Avg. Volume875,524
Market Cap55.149M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-0.9990
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.34
  • GlobeNewswire

    Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 17,000 shares of its common stock to three new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Indu

  • Simply Wall St.

    Broker Revenue Forecasts For Cidara Therapeutics, Inc. (NASDAQ:CDTX) Are Surging Higher

    Celebrations may be in order for Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) shareholders, with the analysts delivering a...

  • Benzinga

    Cidara Therapeutics Stock Slides Despite Acing Rezafungin Trial In Fungal Infection

    Cidara Therapeutics Inc (NASDAQ: CDTX) and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endpoint of all-cause mortality at Day 30 and the primary endpoint for the European Medicines Agency (EMA) submission of global cure at Day 14. Both results demonstrated statistical non-inferiority of rezafungin dosed once-weekly versus caspofungin dosed once-daily, the current standard of care. Rezafungin

Advertisement
Advertisement